{"id":"atazanavir-capsules","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia"},{"rate":"5-10","effect":"Jaundice"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"1-2","effect":"Nephrolithiasis"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that binds to the active site of HIV protease, an enzyme essential for processing viral precursor proteins into functional components. By blocking this enzymatic activity, the drug prevents the formation of mature, infectious viral particles, thereby reducing viral replication and slowing disease progression. It is typically used as part of combination antiretroviral therapy (cART) in HIV-infected patients.","oneSentence":"Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:49.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT04468087","phase":"PHASE2, PHASE3","title":"Antiviral Agents Against COVID-19 Infection","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2021-02-15","conditions":"COVID-19","enrollment":256},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT01620944","phase":"PHASE3","title":"Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07-31","conditions":"HIV","enrollment":3},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT04452565","phase":"PHASE2, PHASE3","title":"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2022-06-15","conditions":"Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":525},{"nctId":"NCT00006604","phase":"PHASE1, PHASE2","title":"Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections","enrollment":195},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02565888","phase":"PHASE1","title":"A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-11","conditions":"Hepatitis C, HIV","enrollment":16},{"nctId":"NCT03708861","phase":"PHASE3","title":"Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients","status":"WITHDRAWN","sponsor":"University of Turin, Italy","startDate":"2016-01","conditions":"HIV Infection","enrollment":""},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02652624","phase":"PHASE3","title":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-02-19","conditions":"HIV-1 Infection","enrollment":472},{"nctId":"NCT00355719","phase":"PHASE4","title":"Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2007-01","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT01803074","phase":"PHASE2","title":"Study to Evaluate a HIV Drug for the Treatment of HIV Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-04-04","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":107},{"nctId":"NCT01705574","phase":"PHASE3","title":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10-24","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":583},{"nctId":"NCT01384734","phase":"PHASE2","title":"HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-07-26","conditions":"Infection, Human Immunodeficiency Virus","enrollment":254},{"nctId":"NCT01335698","phase":"PHASE3","title":"Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-05-27","conditions":"HIV","enrollment":160},{"nctId":"NCT01099579","phase":"PHASE3","title":"PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-10-13","conditions":"HIV Infections","enrollment":82},{"nctId":"NCT01691794","phase":"PHASE4","title":"Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11-30","conditions":"HIV, Pediatric","enrollment":108},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT00720590","phase":"NA","title":"Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2003-11","conditions":"Endothelial Dysfunction","enrollment":30},{"nctId":"NCT01108510","phase":"PHASE3","title":"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":698},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00892437","phase":"PHASE2","title":"Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-05","conditions":"HIV-1 Infection","enrollment":85},{"nctId":"NCT00757783","phase":"PHASE4","title":"Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2008-10","conditions":"HIV","enrollment":68},{"nctId":"NCT01106586","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":708},{"nctId":"NCT00916448","phase":"NA","title":"The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-05","conditions":"Endotoxemia, Inflammation, Multi Organ Dysfunction Syndrome","enrollment":30},{"nctId":"NCT01332227","phase":"PHASE4","title":"Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"HIV, Combination Therapy","enrollment":132},{"nctId":"NCT00551018","phase":"PHASE2","title":"Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"HIV Infections","enrollment":218},{"nctId":"NCT01837719","phase":"PHASE1","title":"Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-04","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1)","enrollment":64},{"nctId":"NCT01102972","phase":"PHASE4","title":"A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":297},{"nctId":"NCT00646776","phase":"PHASE1","title":"Drug Interaction Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-04","conditions":"Antivirals/HIV","enrollment":85},{"nctId":"NCT00224445","phase":"PHASE4","title":"Boosted Atazanavir and Truvada Given Once-Daily - BATON Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2005-09","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT01232127","phase":"PHASE4","title":"Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-02","conditions":"HIV","enrollment":25},{"nctId":"NCT00768989","phase":"PHASE2","title":"Phase IIB Pilot of Atazanavir + Raltegravir","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-11","conditions":"HIV","enrollment":167},{"nctId":"NCT00326716","phase":"PHASE1","title":"Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"HIV Infection","enrollment":69},{"nctId":"NCT00272779","phase":"PHASE3","title":"BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"HIV Infections","enrollment":1057},{"nctId":"NCT00135343","phase":"PHASE3","title":"A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-04","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00067782","phase":"PHASE3","title":"A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00357188","phase":"PHASE1","title":"Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-07","conditions":"HIV Infections, Protease Inhibitor","enrollment":22},{"nctId":"NCT00357604","phase":"PHASE1","title":"Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-07","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT00162149","phase":"PHASE1","title":"ATV/Ritonavir Nevirapine Interaction (USPAC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-10","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT00357240","phase":"PHASE1","title":"Drug Interaction Study With Proton Pump Inhibitor","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00362726","phase":"PHASE1","title":"Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-09","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT00393328","phase":"PHASE1","title":"Bioequivalence Study of Atazanavir 300 mg Capsule","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-11","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT00357721","phase":"PHASE1","title":"Atazanavir Twice Daily","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"HIV Infections, Protease Inhibitor","enrollment":18},{"nctId":"NCT00035932","phase":"PHASE3","title":"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-11","conditions":"HIV Infections","enrollment":571},{"nctId":"NCT00337467","phase":"PHASE3","title":"Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"Human Immunodeficiency Virus (HIV) Infections","enrollment":61},{"nctId":"NCT00135356","phase":"PHASE4","title":"Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"HIV-Associated Lipodystrophy Syndrome","enrollment":219},{"nctId":"NCT00084253","phase":"PHASE4","title":"Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-06","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00384904","phase":"PHASE4","title":"Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00120393","phase":"PHASE3","title":"Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-01","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00135395","phase":"PHASE3","title":"A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00518297","phase":"PHASE1","title":"DDI HV (ATV - Merck)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-08","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT00207142","phase":"PHASE4","title":"Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"HIV Infections","enrollment":252},{"nctId":"NCT00192608","phase":"NA","title":"A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-11","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00420355","phase":"PHASE4","title":"Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients","status":"TERMINATED","sponsor":"University of Oklahoma","startDate":"2007-04","conditions":"HIV Infection","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atazanavir capsules","genericName":"Atazanavir capsules","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}